ArticleGastroenterology2018
Prognostic Utility of Total
Article in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- PET/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review.EJNMMI reports · 2026Review
- Improved patient models for simulation of clinically realisticEJNMMI physics · 2026Article
- PSMA PET/CT-Derived Indicators and Outcomes After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- SUV-max ofJournal of neuro-oncology · 2025Article
- Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors.Biomedicines · 2025Article
- [Cancers · 2025Article
- Progress report on multiple endocrine neoplasia type 1.Familial cancer · 2025Review
- Prognostic value ofFrontiers in cardiovascular medicine · 2025Article
- Role ofFrontiers in medicine · 2025Article
- Inter- and intra-tumoral heterogeneity on [EJNMMI reports · 2024Article
- Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours.EJNMMI research · 2024Article
- Retrospective evaluation of the predictive value of tumour burden at baseline [EJNMMI reports · 2024Article
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.Annals of surgical oncology · 2023Article
- Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.Journal of cancer research and clinical oncology · 2023Article
- Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs).Life (Basel, Switzerland) · 2023Review
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 4 countries.
Funding
Abstract
BACKGROUND &
aimsSurvival times vary among patients with neuroendocrine tumors (NETs) - even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs because some patients can survive decades without treatment.
methodsWe performed a prospective study of 184 patients with NETs (128 [69.6%] with metastases and 11 patients [6.0%] with locally advanced disease) at the National Institutes of Health Clinical Center (Bethesda, MD) from 2013 through 2017. All patients underwent
resultsWe found an inverse correlation between quartiles of
conclusionsIn a prospective study, we demonstrated the prognostic utility of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.